The Singapore Clinical Research Institute (SCRI) is the national academic research organisation dedicated to enhancing the standards of clinical research and coordinating clinical trials.
Our mission is to spearhead and develop core capabilities, infrastructure and scientific leadership for clinical research in Singapore. SCRI also works with the National Medical Research Council (NMRC) to assist the Ministry of Health (MOH) in implementing clinical trials policy and strategic initiatives to support and develop clinical research competencies locally.
In driving towards its vision, SCRI collaborates with clinicians to enhance Singapore’s clinical research and strengthen its expertise in executing multi-site, multi-national studies and the development of regional clinical research networks.
For more information, please visit http://www.scri.edu.sg
The National Health Innovation Centre Singapore (NHIC) aims to provide the publicly-funded clinical research sector of Singapore with translational funding and strategic guidance.
Established in 2014, NHIC impacts the clinical landscape by accelerating the development of innovative technologies and services to improve healthcare delivery and patient care. NHIC funding and guidance supports the translation of an innovation by validating, de-risking or developing it towards a market-ready product.
By promoting the collaboration of researchers, clinicians and industry, NHIC strives to better position Singapore to tackle the healthcare challenges of tomorrow.
For more information, please visit www.nhic.sg
The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established on 20 April 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. ACTRIS’s vision is to be the national and regional Centre of Excellence for discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approval products for the local market.
ACTRIS aims to achieve accreditation from national and international regulators to ensure quality compliance of resource-efficient cellular therapy manufacturing. Our common goal is to promote and foster the entire value chain of the cellular therapy ecosystem through enabling translational research and development, manufacturing, clinical service provision and commercialisation by serving the healthcare, academic and industrial sectors. ACTRIS will also provide value-added services such as workforce training, regulatory facilitation and ancillary material standardization pertaining to delivery of cellular therapy to patients.
For more information, please visit https://www.actris.sg/
Precision Health Research, Singapore (PRECISE)
Precision Health Research, Singapore (PRECISE) is the central entity set up to coordinate a whole of government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy.
NPM Phase II aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions. NPM Phase II will also enhance the breadth and depth of the Precision Medicine-related industry by attracting and anchoring overseas companies in Singapore, while yielding new opportunities for home-grown companies.
For more information, please visit https://www.npm.sg/
The Singapore Translational Cancer Consortium (STCC) is a nationally-coordinated consortium to synergise cancer research capabilities in Singapore.
Established in 2020, STCC brings together unmatched basic, clinical and translational talent in Singapore to create globally significant peaks of excellence in selected Asian cancers. STCC’s four joint platforms – Clinical Trials and Investigational Medicine Units, Cancer Database and Tissue Banks, Translational Assays and Models, and the Business Intelligence and Development Unit – provide an enabling research and innovation environment driven to foster translational research with meaningful outcomes for society.
Through these forged collaborative relationships between local cancer research groups and by capitalising on the strengths of industry and academia, STCC is uniquely poised to develop initiatives that are aligned with Singapore’s goals in value-based healthcare innovation and economic value creation.
For more information, please visit www.stcc.sg